Management of patients with intermittent claudication

International Journal of Clinical Practice

Volumn 56, Issue 9, 2002, Pages 687-693

  Olin, J W ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BERAPROST; CARNITINE DERIVATIVE; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 INHIBITOR; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDETIC ACID; ERYTHROMYCIN; FISH OIL; KETANSERIN; METHYLXANTHINE DERIVATIVE; NIFEDIPINE; OMEPRAZOLE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; RAMIPRIL; TICLOPIDINE;

ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; HEADACHE; HUMAN; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; LEG DISEASE; LEG REVASCULARIZATION; LIFESTYLE; MORBIDITY; MORTALITY; NEUTROPENIA; PHYSICAL DISABILITY; PRIORITY JOURNAL; REST; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE; SYMPTOMATOLOGY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; VERTIGO;

ASPIRIN; BLOOD VESSEL PROSTHESIS; EXERCISE THERAPY; HUMANS; INTERMITTENT CLAUDICATION; MEDICAL HISTORY TAKING; PENTOXIFYLLINE; PHYSICAL EXAMINATION; PLATELET AGGREGATION INHIBITORS; TETRAZOLES; TICLOPIDINE; VASODILATOR AGENTS;

EID: 0036858298     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. TASC Working Group. Management of peripheral arterial disease (peripheral arterial disease): TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31(1 pt 2, suppl): S1-S296.
2. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386.
3. Vogt MT, Cauley JA, Newman AB et al. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993; 270: 465-469.
4. Weitz JI, Byrne J, Clagett GP et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996; 94: 3026-3049.
5. Regensteiner JG, Treat-Jacobson D, Walsh ME, Hiatt WR. Partners: the impact of peripheral arterial disease (peripheral arterial disease) on health-related quality of life (HQL). Circulation 2000; 102(suppl II): II-400. Abstract 1948.
6. Hirsch AT, Criqui MH, Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-1324.
7. McLafferty RB, Dunnington GL, Mattos MA et al. Factors affecting the diagnosis of peripheral vascular disease before vascular surgery referral. J Vasc Surg 2000; 31: 870-879.
8. Dormandy J, Heeck L, Vig S. Intermittent claudication: a condition with underrated risks. Semin Vasc Surg 1999; 12: 96-108.
9. Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg 1999; 12: 123-137.
10. Fowkes FG, Housley E, Riemersma RA et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992; 135: 331-340.
11. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-1057.
12. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985; 33: 13-18.
13. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. Circulation 1995; 91: 1472-1479.
14. Krajewski LP, Olin JW. Atherosclerosis of the aorta and lower extremity arteries. In: Young JR, Olin JW, Bartholomew JR, Eds. Peripheral vascular diseases, 2nd edn. Mosby: 1996: 208-233.
15. McGee SR, Boyko EJ. Physical examination and chronic lower-extremity ischemia. Arch Intern Med 1998; 138: 1357-1364.
16. Olin JW. Clinical evaluation and office-based detection of peripheral arterial disease. In: An office-based approach to the diagnosis and treatment of peripheral arterial disease. Am J Med 'Continuing Medical Education Series', 1998: 10-17.
17. McDermott MM. Ankle brachial index as a predictor of outcomes in peripheral arterial disease. J Lab Clin Med 1999; 133: 33-40.
18. Creager MA. Clinical assessment of the patient with claudication: the role of the vascular laboratory. Vasc Med 1997; 2: 231-237.
19. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust 1983; 1: 217-219.
20. Hirsch AT, Treat-Jacobson D, Lando HA, Hatsukami DK. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med 1997; 2: 243-251.
21. Girolami B, Bernardi E, Prins MH et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl. Arch Intern Med 1999; 159: 337-345.
22. Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications trial. Diabetes Care 1995; 18: 361-376.
23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with suphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.
24. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control on complications in overweight patients with type 2 diabetes. Lancet 1998; 352: 854-865.
25. Pedersen TR. Kjekshus J, Pyorala K et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998; 81: 333-335.
26. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486-2496.
27. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. JAMA 1995; 274: 975-980.
28. Regensteiner JG, Meyer TJ, Krupski WC et al. Hospital versus home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology 1997; 48: 291-300.
29. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 1998; 114(suppl): 666S-682S.
30. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. Can Med Assoc J 1996; 155: 1053-1059.
31. Porter JM, Cutler BS, Lee BY et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982; 104: 66-72.
32. Gallus AS, Gleadow F, Dupont P et al. Intermittent claudication: a double-blind crossover trial of pentoxifylline. Aust NZ J Med 1985; 5: 402-409.
33. Reilly DT, Quinton DN, Barrie WW. A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects. NZ Med J 1987; 100: 445-447.
34. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523-530.
35. Trental (package insert). Kansas City, MO: Hoechst-Roussel Pharmaceuticals, 1998.
36. Pletal (package insert). Gaithersburg, MD: Otsuka Pharmaceuticals, 1999.
37. Dawson DL, Cutler BS, Meissner MH, Strandness DE, Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678-686.
38. Money SR, Herd JA, Isaacsohn JL et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27: 267-275.
39. Beebe HG, Dawson DL, Cutler BS et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159: 2041-2050.
40. Lievre M, Morand S, Besse B et al, on behalf of the Beraprost et Claudication Intermittente (BERCI) Research Group. Oral beraprost sodium, a prostaglandin I2 analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Circulation 2000; 102: 426-431.
41. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
42. Goldhaber SZ, Manson JE, Stampfer MJ et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 1992; 340: 143-145.
43. Janzon L, Bergqvist D, Boberg J et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227: 301-308.
44. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
45. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.